LifeMD reported third-quarter revenue of $44.6 million, below $48 to $51 million guidance, and cut 2026 revenue guidance to $188 million to $191 million from $205.5 million to $212.5 million. Adjusted EBITDA was a $0.4 million loss.
LFMD · LifeMD, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 77%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
LifeMD reported third-quarter revenue of approximately $44.6 million, down 7%, and gross profit of approximately $36.4 million, down 11%, as telehealth costs rose to 18% of revenue from 15%.
LifeMD closed a $12.5 million secured loan on November 9, 2026 and terminated its Citizens credit facility with no amounts outstanding; the loan matures May 1, 2030 at the greater of 4.50% plus the Prime Rate or 11.50%.
LifeMD, Inc. delayed its September 30, 2026 quarterly filing because corrections require more time. Adjustments address revenue and expense recognition errors for 2024 through June 30, 2026; cash flow and cash position are unaffected.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. LifeMD reported Q2 revenue of $47.3 million within guidance but adjusted EBITDA of a $3.5 million loss, missing its own target due to elevated customer acquisition costs and a new $39 introductory GLP-1 price; the company sharply lowered full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven EBITDA, while reiterating a Q4 exit run rate of ~$250M revenue and ~$22M annualized EBITDA.
- + Recurring rebill revenue grew to ~84% of total revenue, supporting a higher-quality revenue base.
- + Weight management pricing shift drove multi-month package selection from ~25% to ~85%, improving patient LTV.
- − Q2 adjusted EBITDA missed guidance at a loss of ~$3.5M due to elevated acquisition costs and the $39 introductory offer.
- − Full-year 2026 revenue guidance cut to $205.5M–$212.5M from prior $220M–$230M.
- − Full-year 2026 adjusted EBITDA guidance cut to negative $6M to breakeven from prior $12M–$17M.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active Subscribers | 349,744 | Q3 FY2026 | — |
| Adjusted EBITDA non-GAAP | -$8,559,991 | Nine Months Ended September 30, 2026 | — |
| Telehealth costs as % of associated telehealth revenues | 18% | the three months ended September 30, 2026 filing | — |
| Weight Management Program subscribers | 108,000 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LFMD
this stock
LifeMD, Inc.
|
$69.84M | -57.6% | +49.8% | — | 15.0% |
|
VEEV
Veeva Systems Inc
|
$43.10B | +19.3% | +28.1% | 43.6 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.50B | +67.8% | +28.2% | 34.2 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$9.86B | -8.5% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 17
LifeMD reported third-quarter revenue of approximately $44.6 million, down 7%, and gross profit of approximately $36.4 million, down 11%, as telehealth costs rose to 18% of revenue from 15%.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LFMD | -34.2% | -32.2% | -69.2% | -36.9% | -57.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -25.6% | -22.9% | -60.0% | -28.2% | -58.8% |